ESTRO 2024 - Abstract Book

S2341

Clinical - Urology

ESTRO 2024

We demonstrated that EBRT combined with ADT and followed by a single-fraction HDR-brachytherapy boost leads to high rates of biochemical disease-free- and overall survival in a large prospective cohort of predominantly high risk prostate cancer patients, while maintaining acceptable toxicity rates and having a small impact on quality of life. PSA nadir after treatment is a powerful predictor of recurrence during follow-up.

Keywords: Prostate, HDR, boost

References:

1. Oh J, Tyldesley S, Pai H, et al. An updated analysis of the survival endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys 2022;115:1061 – 1070.

2. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:286 – 95. 3. Ka K, Schiappa R, Terlizzi M, et al. Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy group. Radiotherapy and Oncology 180 (2023) 109460. 4. M. Miszczyk, Ł. Magrowski, T. Krzysztofiak et al. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. Radiotherapy and Oncology 183 (2023) 109632.

551

Digital Poster

Real world prostate SABR - the Glasgow experience

Kirsty Nash, Rebecca Carozzi, Stephanie Anderson, Helena Belikova, Abdulla Alhasso, Nicholas MacLeod, Carolynn Lamb

Beatson West of Scotland Cancer Centre, Radiotherapy, Glasgow, United Kingdom

Purpose/Objective:

Prostate cancer is the most common cancer among men in the UK¹. Stereotactic ablative body radiotherapy (SABR) for localised disease² permits a shorter treatment course with equivalent failure free survival outcomes to standard of care, modest hypofractionation (20 fraction) radiotherapy³. We review our use of off-trial linear-accelerator (lin acc)-based prostate SABR, focussing on prospectively collected, clinician-reported acute toxicity.

Material/Methods: